Warrenton

Researchers are observing how avacincaptad pegol is used in routine clinical practice for people with geographic atrophy caused by age-related macular degeneration AMD. Geographic atrophy is an advanced form of AMD where retinal cells waste away, leading to worsening central vision and potential permanent vision loss. This observational study collects information on treatment and medical events related to avacincaptad pegol without influencing the doctors treatment decisions. Participants in this study have chosen to begin treatment with avacincaptad pegol, delivered as intravitreal injections into the eye. The study records how often and how long the treatment is given, along with reasons for stopping treatment. It monitors participants receiving this treatment in one or both eyes as part of their regular medical care, without additional interventions from the study. During the study, participants will have eye exams as part of their usual care and will complete surveys about their eye health at the start of treatment, every six months for two years, and then yearly. Researchers will gather data from medical records to track treatment usage, vision changes, and any adverse events for up to about five years. This long-term observation helps understand real-world treatment patterns and safety.

Researchers are conducting a phase 3 randomized, double-masked clinical trial to compare the effects of two treatments, EYP-1901 and Aflibercept, for patients with diabetic macular edema DME. This study aims to evaluate which treatment better improves visual acuity in people affected by this condition. EyePoint Pharmaceuticals, Inc. is leading this study to assess these injectable drugs impact on vision. Participants will receive either EYP-1901 or Aflibercept through intravitreal injections directly into the eye. The study uses a parallel assignment design with participants randomized to one of the two treatment groups. The trial is double-masked to ensure unbiased results, and the primary treatment period focuses on 52 to 56 weeks of follow-up after injections. During the study, participants will have their best-corrected visual acuity measured to assess changes in vision. Researchers will also monitor the frequency of injections required over the 56-week period to evaluate treatment burden. Participants will attend regular study visits for these assessments and safety monitoring throughout the trial duration, which ends in October 2028.